Research progress of targeting PD-1/PD-L1 in immunotherapy for non-small-cell lung cancer
10.3760/cma.j.issn.1006-9801.2015.10.017
- VernacularTitle:细胞程序性死亡受体-1及其配体在非小细胞肺癌免疫治疗中的研究进展
- Author:
Li PAN
;
Rui GENG
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Programmed death-1;
Programmed death ligand-1;
Epithelial growth factor receptor;
Immunotherapy
- From:
Cancer Research and Clinic
2015;27(10):711-713
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the leading cause of cancer-related death in the world.PD-1 is a member of the CD28 family expressed on the surface of a variety of immune cells.PD-L1, one of PD-1 ligands, plays a pivotal role in the ability of tumor cells to evade the host immune system.A recent study showed that signaling via mutant EGFR in lung tumor cells upregulates directly tumor PD-L1 expression.In this review, the clinical significance of the PD-1/PD-L1 pathway in immunotherapy for non-small-cell lung cancer (NSCLC) and the relevance to targeted therapy were summarized.
